The Role of Mesencephalic Astrocyte-Derived Neurotrophic Factor (MANF) in Biomarkers of Diabetic Nephropathy

Abstract

Objective: This study investigates the potential role of Mesencephalic Astrocyte-Derived Neurotrophic Factor (MANF) as a novel biomarker, evaluating its associations with established urinary biomarkers and glycemic control indicators in diabetes mellitus and diabetic nephropathy (DN). Methods: A cross-sectional study was conducted involving 84 participants stratified by albuminuria levels into normoalbuminuria, microalbuminuria, and macroalbuminuria groups. MANF levels were quantified using enzyme-linked immunosorbent assays (ELISA), while urinary biomarkers and HbA1C were measured using standard clinical methods. Correlation analyses and multivariate regression models were employed to assess relationships between MANF and biomarkers. Results: MANF levels demonstrated a significant upward trend across albuminuria categories, with the highest levels observed in the macroalbuminuria group (514.5±112.3 pg/mL, p<0.01). MANF positively correlated with HbA1C (R=0.78, p<0.001) and negatively with estimated glomerular filtration rate (eGFR) (R=0.72, p<0.001). These associations remained significant after adjusting for confounders such as age, sex, and body mass index (BMI). Conclusion: MANF is a promising biomarker that reflects glycemic dysregulation and renal dysfunction, offering potential advantages over traditional markers. Its integration into clinical practice could enhance the early detection and personalized management of chronic kidney disease (CKD) and diabetes. Future longitudinal studies are warranted to validate its predictive value.

Keywords

• Kidney Diseases
• Chronic
• Diabetic Nephropaties
• Biological Markers
• Blood Glucose
• Neurotrophic Factors

References

1. Fassett RG, Venuthurupalli SK, Gobe GC, Coombes JS, Cooper MA, Hoy WE. Biomarkers in chronic kidney disease: a review. Kidney Int. 2011;80(8):806-821. doi:10.1038/ki.2011.198
2. Zhao YY. Metabolomics in chronic kidney disease. Clin Chim Acta. 2013;422:59-69. doi:10.1016/j.cca.2013.03.033
3. Wasung ME, Chawla LS, Madero M. Biomarkers of renal function, which and when? Clin Chim Acta. 2015;438:350-357. doi:10.1016/j.cca.2014.08.039
4. Julkunen H. Metabolic blood biomarker profiling for chronic kidney disease prediction. Nephrol Dial Transplant. 2023;38. doi:10.1093/ndt/gfad063c_5650
5. Tesch GH. Review: Serum and urine biomarkers of kidney disease: a pathophysiological perspective. Nephrology (Carlton). 2010;15(6):609-616. doi:10.1111/j.1440- 1797.2010.01361.x
6. Zhang ZH, Chen H, Vaziri ND, et al. Metabolomic signatures of chronic kidney disease of diverse etiologies in the rats and humans. J Proteome Res. 2016;15(10):3802-3812. doi:10.1021/acs.jproteome.6b00583
7. Breit M, Weinberger KM. Metabolic biomarkers for chronic kidney disease. Arch Biochem Biophys. 2016;589:62-80. doi:10.1016/j.abb.2015.07.018
8. Kim Y, Lee H, Manson SR, et al. Mesencephalic astrocytederived neurotrophic factor as a urine biomarker for endoplasmic reticulum stress-related kidney diseases. J Am Soc Nephrol. 2016;27(10):2974-2982. doi:10.1681/ASN.2014100986

9. Liu H, Tang X, Gong L. Mesencephalic astrocyte-derived neurotrophic factor and cerebral dopamine neurotrophic factor: new endoplasmic reticulum stress response proteins. Eur J Pharmacol. 2015;750:118-122. doi:10.1016/j.ejphar.2015.01.016
10. Lindahl M, Danilova T, Palm E, et al. MANF is indispensable for the proliferation and survival of pancreatic β cells. Cell Rep. 2014;7(2):366-375. doi:10.1016/j.celrep.2014.03.023
11. Kim WJ, Park CY, Lee KB, et al. Serum 1,5-anhydroglucitol concentrations are a reliable index of glycemic control in type 2 diabetes with mild or moderate renal dysfunction. Diabetes Care. 2012;35(2):281-286. doi:10.2337/dc11-1462
12. Zhang H, Zuo JJ, Dong SS, et al. Identification of potential serum metabolic biomarkers of diabetic kidney disease: a widely targeted metabolomics study. J Diabetes Res. 2020;2020:3049098. doi:10.1155/2020/3049098
13. Inaba M, Okuno S, Kumeda Y, et al. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J Am Soc Nephrol. 2007;18(3):896- 903. doi:10.1681/ASN.2006070772
14. Dozio E, Corradi V, Proglio M, et al. Usefulness of glycated albumin as a biomarker for glucose control and prognostic factor in chronic kidney disease patients on dialysis (CKDG5D). Diabetes Res Clin Pract. 2018;140:9-17. doi:10.1016/j.diabres.2018.03.017
15. Looker HC, Colombo M, Hess S, et al. Biomarkers of rapid chronic kidney disease progression in type 2 diabetes. Kidney Int. 2015;88(4):888-896. doi:10.1038/ki.2015.199
16. Zelnick LR, Batacchi ZO, Ahmad I, et al. Continuous glucose monitoring and use of alternative markers to assess glycemia in chronic kidney disease. Diabetes Care. 2020;43(10):2379- 2387. doi:10.2337/dc20-0915
17. Mizdrak M, Kumrić M, Kurir TT, Božić J. Emerging biomarkers for early detection of chronic kidney disease. J Pers Med. 2022;12(4):548. doi:10.3390/jpm12040548
18. Speeckaert M, Van Biesen W, Delanghe J, et al. Are there better alternatives than haemoglobin A1c to estimate glycaemic control in the chronic kidney disease population? Nephrol Dial Transplant. 2014;29(12):2167-2177. doi:10.1093/ndt/gfu006
19. Chaudhary K, Phadke G, Nistala R, Weidmeyer CE, McFarlane SI, Whaley-Connell A. The emerging role of biomarkers in diabetic and hypertensive chronic kidney disease. Curr Diab Rep. 2010;10(1):37-42. doi:10.1007/s11892-009-0080-z
20. Lousa I, Reis F, Beirão I, Alves R, Belo L, Santos-Silva A. New potential biomarkers for chronic kidney disease management— a review of the literature. Int J Mol Sci. 2020;22(1):43. doi:10.3390/ijms22010043
21. Galindo RJ, Beck RW, Scioscia MF, Umpierrez GE, Tuttle KR. Glycemic monitoring and management in advanced chronic kidney disease. Endocr Rev. 2020;41(5):756-774. doi:10.1210/endrev/bnaa017
22. Cardenas-Gonzalez M, Srivastava A, Pavkovic M, et al. Identification, confirmation, and replication of novel urinary microRNA biomarkers in lupus nephritis and diabetic nephropathy. Clin Chem. 2017;63(9):1515-1526. doi:10.1373/clinchem.2017.274175
23. Lecamwasam A, Ekinci EI, Saffery R, Dwyer KM. Potential for novel biomarkers in diabetes-associated chronic kidney disease: epigenome, metabolome, and gut microbiome. Biomedicines. 2020;8(9):341. doi:10.3390/biomedicines8090341